RESUMO

Leflunomide belongs in the group of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of psoriatic, rheumatoid, and reactive arthritis. Approximately 20 % of patients will experience some adverse event, mainly weight loss, abdominal pain, and diarrhea. We describe the clinical, endoscopic, and histological findings in a patient with psoriatic arthritis (PA) who developed severe chronic diarrhea after drug use.

Assuntos

Antirreumáticos , Artrite Reumatoide , Colite Colagenosa , Antirreumáticos/efeitos adversos , Artrite Reumatoide/tratamento farmacológico , Colite Colagenosa/induzido quimicamente , Colite Colagenosa/tratamento farmacológico , Humanos , Isoxazóis/efeitos adversos , Leflunomida/uso terapêutico